The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | An NGS liquid biopsy approach vs standard bone marrow FISH for genomic characterization in myeloma
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses a pilot study evaluating a peripheral blood NGS liquid biopsy approach for genomic profiling of monoclonal gammopathies and multiple myeloma. He highlights the correlation between liquid biopsy and bone marrow findings, the ability to detect additional genetic alterations, and the potential for blood-based testing to complement future disease assessment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
